Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000671885 | SCV000796915 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-01-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001868257 | SCV002278862 | likely pathogenic | not provided | 2022-03-10 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 555962). This variant has not been reported in the literature in individuals affected with USH2A-related conditions. This variant is present in population databases (rs762608746, gnomAD 0.01%). This sequence change affects a splice site in intron 40 of the USH2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |
Genome- |
RCV003446320 | SCV004172079 | likely pathogenic | Retinitis pigmentosa 39 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003446319 | SCV004172080 | likely pathogenic | Usher syndrome type 2A | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003446320 | SCV004208371 | likely pathogenic | Retinitis pigmentosa 39 | 2023-07-27 | criteria provided, single submitter | clinical testing |